---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-021176"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:46:30.194663+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M

## Summary
- Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.
- Q4 2025 gross margin 21% (up from 15% Q4 2024), a company record; full-year gross margin 17% in line with guidance.
- Full-year 2025 net loss $5.3M (vs $0.5M loss in 2024) including $4.0M non-cash charges and $1.2M severance/facility costs.
- Adjusted EBITDA Q4 2025 $1.0M; full-year $0.3M, second consecutive profitable year on that basis; cash grew to $25.0M.
- 2026 guidance: Adjusted EBITDA $1M–$2M, positive operating cash flow; pricing increase under extended purchase agreement through Dec 2026.

## SEC filing metadata
- accession: 0001628280-26-021176
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/0001628280-26-021176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/rmti-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-021176
- JSON: https://secwatch.observer/filing/0001628280-26-021176.json
- Plain text: https://secwatch.observer/filing/0001628280-26-021176.txt

## Key facts
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2025 results: revenue $18.3 million, net income $ (0.6) million, EPS $ (0.01) per share.
  - Period: the three months ended December 31, 2025
  - Revenue: $18.3 million
  - Net income: $ (0.6) million
  - EPS: $ (0.01) per share
  - Result: reported results
  source text: EX-99.1 (EX-99.1) --- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/0001628280-26-021176-index.htm
- Earnings Releases
  ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2025 results: revenue $69.3 million, net income $ (5.3) million, EPS $ (0.15) per share.
  - Period: the twelve months ended December 31, 2025
  - Revenue: $69.3 million
  - Net income: $ (5.3) million
  - EPS: $ (0.15) per share
  - Result: reported results
  source text: --- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth quarter 2025,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/0001628280-26-021176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.